Presenter's Information
Dominick J. Angiolillo, MD
Country | USA |
Specialty | Interventional Cardiologist |
- Antithrombotic Therapy in ACS-PCI
- Don't Forget About Dual Pathway Inhibition: When DOAC Should Not Be Standard Treatment
- Evolving Antithrombotic Strategies for Patients with DM and CAD
- Escalation and De-Escalation Strategy for DAPT: Rationale and Evidence
- COVID-19 and Thrombotic or Thromboembolic Disease
- Tailoring Antithrombotic Therapy in HBR Patient
- Switching Strategy with Contemporary P2Y12 Inhibitor: Escalation and De-escalation
- \"Who Are HBR Patients?\" - Identification of HBR Patients in Clinical Practice
- Aspirin Plus P2Y12 Inhibitor Still Remains as a Key Player.
- Why DAPT Trial Not Followed?: Moving Forward Less Duration with Smart DES, De-Escalating Strategy, and P2Y12 Inhibitor Monotherapy
- Unment Needs and Alternatives to Clopidogrel in Patients with ACS Undergoing PCI
- [Platelet Function Tests-Buckling the Belief] Against: Not Necessary, Time to Forget
- Clopidogrel Classic vs. New Therapies: PLATO and More
- Platelet Inhibitors: Long Term Administration and Monitoring Issues 2013 Resolution